Two-hour cyclosporine concentration determination: An appropriate tool to monitor neoral therapy?

Therapeutic Drug Monitoring

Volumn 24, Issue 1, 2002, Pages 40-46

  Oellerich, Michael ^a   Armstrong, Victor William ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

C2 monitoring; Cyclosporine; Transplantation

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A;

ADULT; AGED; ANALYTIC METHOD; AREA UNDER THE CURVE; BLOOD SAMPLING; CONFERENCE PAPER; DRUG DETERMINATION; DRUG MONITORING; FEMALE; GASTROINTESTINAL ABSORPTION; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INDIVIDUALIZATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECIPIENT;

AREA UNDER CURVE; CYCLOSPORINE; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 0036150427     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200202000-00008     Document Type: Conference Paper

References (38)

1. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: Report of the consensus panel
2. Critical issues in cyclosporine monitoring: Report of the Task Force on Cyclosporine Monitoring
3. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine
4. Optimization of cyclosporine therapy with new therapeutic drug monitoring strategies: Report from the international Neoral® TDM advisory consensus meeting (Vancouver, November 1997)
5. Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus
6. Limited sampling strategies for estimating cyclosporine area under the concentration-time curve: Review of current algorithms
7. Improved graft survival after renal transplantation in the United States, 1988 to 1996
8. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group
9. Cyclosporine monitoring in patients with renal transplants: Two- or three-point methods that estimate area under the curve are superior to trough levels in predicting drug exposure
10. The Neoral formulation: Improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients
11. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients - A concentration-controlled comparison with the commercial formulation
12. Pharmacokinetics of a new oral formulation of cyclosporine in liver transplant recipients
13. Comparison of conventional oral cyclosporine and cyclosporine microemulsion formulations in children with a liver transplant
14. Pharmacokinetics of cyclosporine in pediatric long-term liver transplant recipients converted from Sandimmun to Neoral
15. Neoral absorption profiling: An evolution in effectiveness
16. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation
17. Kidney function after 1:1 conversion to the cyclosporine microemulsion formulation in children with liver allografts
18. The temporal profile of calcineurin inhibition by cyclosporine in vivo
19. Inhibition of stimulated interleukin-2 production in whole blood: A practical measure of cyclosporine effect
20. In renal transplant recipients whole blood calcineurin activity is not predicted by cyclosporine blood levels
21. Neoral monitoring by simplified sparse sampling area under the concentrationtime curve
22. Absorption profiling: A novel method for monitoring neoral in kidney transplantation that reduces rejection and nephrotoxicity
23. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection. Results of a prospective, randomized comparison of Neoral and Sandimmune for liver transplantation (NOF-8)
24. Role of intestinal Pglycoprotein (mdrl) in interpatient variation in the oral bioavailability of cyclosporine
25. Pharmacokinetic validation of Neoral absorption profiling
26. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP 3A4-V allele) on doseadjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients
27. Improved clinical outcomes for liver transplant recipients using cyclosporine blood level monitoring based on two-hour post-dose levels
28. Benefits of cyclosporine microemulsion (Neoral®) C-2 monitoring are sustained at one year in de novo liver transplant recipients
29. C-2 monitoring in liver transplantation with Neoral immunosuppression: Effect of achieving C-2 target early on efficacy and safety
30. Comparison of Neoral dose monitoring with cyclosporine through levels versus 2-hour postdose levels in stable liver transplant patients
31. Clinical benefit of Neoral dose monitoring with cyclosporine 2-hour postdose levels compared with trough levels in stable heart transplant patients
32. 2 cyclosporine monitoring using Neoral immunosuppression in maintenance liver transplant patients improvement in renal function and hypertension
33. Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients
34. Microscale high-performance liquid chromatographyelectrospray tandem mass spectrometry assay for cyclosporin A in blood
35. Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and Emit): A critical overview of performance characteristics and comparison with HPLC
36. Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: How specific is specific?
37. CsA immunoassays in comparison to LC-MS/MS, is there a difference betwen trough (CO) and C2 levels?
38. New approaches to cyclosporine monitoring raise further concerns about analytical techniques